Related Experiment Video
Updated: May 21, 2026
07:02
In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
Published on: August 23, 2019
Diagnostic and prognostic markers in differentiated thyroid cancer
1Endocrinology and Nutrition Service, University Hospital of Bellvitge, L´Hospitalet of Llobregat, Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), Barcelona, Spain.
Current Genomics
|June 2, 2012
Summary
Alterations in MAPK/ERK and PI3K/Akt pathways drive thyroid cancer by affecting cell growth and apoptosis. Genetic and epigenetic changes in these pathways, including methylation, are key to tumorigenesis and tumor aggressiveness.
Area of Science:
- Molecular Biology
- Oncology
- Genetics
Background:
- The mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) and phosphoinositide-3-kinase/Akt (PI3K/Akt) signaling pathways are crucial for cellular signal transduction, regulating cell growth, proliferation, and apoptosis.
- Aberrant signaling in these pathways is implicated in various cancers, including thyroid cancer.
Purpose of the Study:
- To explore the role of genetic and epigenetic alterations in the MAPK/ERK and PI3K/Akt signaling pathways in thyroid cancer development and progression.
- To present current diagnostic and prognostic genetic/epigenetic markers associated with thyroid tumorigenesis.
Main Methods:
- Review of literature on genetic and epigenetic alterations in thyroid cancer.
- Analysis of gene mutations and aberrant expression within the MAPK/ERK and PI3K/Akt signaling cascades.
- Investigation of DNA methylation patterns in tumor suppressor and thyroid-specific genes.
Main Results:
- Mutations and aberrant expression of key genes (RET, RAS, BRAF, PI3K, PTEN, AKT) in the MAPK/ERK and PI3K/Akt pathways are observed in thyroid cancer.
- Genetic and epigenetic changes contribute to the activation and interaction of these pathways, promoting malignant transformation.
- Aberrant DNA methylation is linked to tumor aggressiveness and thyroid tumorigenesis.
Conclusions:
- Understanding the molecular mechanisms of MAPK/ERK and PI3K/Akt pathway dysregulation in thyroid cancer is essential.
- Genetic and epigenetic markers offer potential for improved diagnosis and prognosis.
- This knowledge facilitates the development of novel molecular therapeutic strategies for thyroid cancer.
